Effects of Confomational Change on the Angiogenic Activty of Threonyl-tRNA Synthetase by Abdi, Khadar H.
University of Vermont
ScholarWorks @ UVM
UVM College of Arts and Sciences College Honors
Theses Undergraduate Theses
2017
Effects of Confomational Change on the
Angiogenic Activty of Threonyl-tRNA Synthetase
Khadar H. Abdi
University of Vermont
Follow this and additional works at: https://scholarworks.uvm.edu/castheses
This Undergraduate Thesis is brought to you for free and open access by the Undergraduate Theses at ScholarWorks @ UVM. It has been accepted for
inclusion in UVM College of Arts and Sciences College Honors Theses by an authorized administrator of ScholarWorks @ UVM. For more
information, please contact donna.omalley@uvm.edu.
Recommended Citation
Abdi, Khadar H., "Effects of Confomational Change on the Angiogenic Activty of Threonyl-tRNA Synthetase" (2017). UVM College of




Effects of Conformational Change on the Angiogenic Activity of Threonyl-tRNA 
Synthetase 
 
Defense presented by: Khadar Abdi 
 
Performed at the University of Vermont in College of Arts and Science 
 







 This project was done with the help of all the members of Francklyn and Lounsbury lab 
including: Jamie Abbot, Adam Mirando, Shawn Egri, Susan Robey-Bond, Terry Wellman, and 
Patrick Mullen. Many thanks to them for helping me with the techniques and analysis done in the 
lab and giving me positive feedback. Thanks also goes to both Dr. Christopher Francklyn and Dr. 
Karen Lounsbury for accepting me into the lab during my junior year and encouraging me to 




List of Abbreviations 




EBM-Endothelial Basal Media 
EGM-Endothelial Growth Media 
E. Coli- Escherichia coli 
HUVECs- Human umbilical vascular endothelial cells 
PBS-Phosphate buffered saline 
SDS-PAGE- Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TARS-Threonyl-tRNA synthetase 








 Aminoacyl-tRNA synthetases (aaRs) have been known for their importance in protein 
synthesis. However, the Francklyn/Lounsbury lab discovered that some aaRs, like tyrosyl-tRNA 
synthetase and tryptophanyl-tRNA synthetase are linked to angiogenesis. Recently, the lab 
discovered that threonyl-tRNA synthetase (TARS) was an angiogenic factor that is linked to 
ovarian cancer. Studies have shown that a derivative of macrolide inhibitor Borrelidin, known as 
BC194, inhibits TARS angiogenic and functional activity and altering TARS conformation. Sites 
of BC19 were found and used to generate mutated version of human TARS. Q566W and H388A 
TARS mutations were investigated to see whether induced conformational change or loss of 
aminoacyl-transferase activity is the key to inhibit angiogenic activity respectively. Q566W and 
H388A plasmids were generated using site-directed mutagenesis. The plasmids were expressed 
in Escherichia coli cells and purified using sonication, protamine sulfate salting, His6tag affinity 
chromatography and Hydroxyapatite chromatography. Purified mutants were found to have a 
molecular weight of 83kDa using sodium dodecyl sulfate polyacrylamide gel electrophoresis.  
Following purification, TARS enzymes were applied to the in vitro tube assay using human 
umbilical vein endothelial cells to test angiogenic activity. Q566W promoted a similar number of 
pieces and branches as wild type TARS, while H388A had the greatest amount tube pieces, 
branches, and branching length. The study didn’t find a difference in angiogenic activity between 
the wild type and mutant TARS. However, the study shows that TARS has dose-dependent 
angiogenic activity and may link to α5β3 intergin migration signaling. More studies on 
angiogenic activity using integrin inhibitor dose response in vitro tube assay under TARS are 
needed to verify this mechanism.    
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I.  Introduction 
 The primary function of aminoacyl-tRNA synthetases (aaRS) is to transfer a specific 
amino acid to an uncharged tRNA containing the corresponding anticodon, which is necessary 
for protein synthesis  (Ibba & Soll, 2000). AaRSs perform this mechanism in a two-step process: 
1) Adding an adenosine monophosphate (AMP) to the amino acid with adenosine triphosphate 2) 
Exchange of AMP with tRNAAA (with AA meaning the specific amino acid).  
Interestingly, studies have linked some human diseases to mutation in aaRS. For instance, 
mutant forms of tyrosyl-tRNA synthetase (YARS) were found to be linked to Charcot-Marie-
Tooth, a peripheral neuropathy disorder causing axonal degeneration starting at upper and lower 
extremities and spreads toward the body (Jordanova et al., 2006). But more surprising was the 
idea that aaRSs are connected with angiogenesis (Keisuke Wakasugi & Schimmel, 1999). 
Angiogenesis, development of new blood vessels from pre-existing ones, is an important 
part of the developing tumor microenvironment (Cassavaugh & Lounsbury, 2011). Tumor 
microenvironments are necessary for survival, growth, and proliferation of cancer cells, as seen 
in ovarian cancer (Wellman et al., 2014). The normal process of angiogenesis includes 
endothelial cell migration that consists of cellular movement involving rearrangement of actin 
filaments resulting in stretching the endothelial cells into a leading tip (Michaelis, 2014). 
Endothelial cell migration during angiogenesis occurs by Vascular Endothelial Growth 
Factor receptor 2 (VEGFR2) signaling mechanism (Lamalice, Le Boeuf, & Huot, 2007). First, 
VEGFR2 activates cdc42, a Rho-GTPase protein, that stimulates the formation of actin stress 
fibers that breakthrough the cell in the direction of VEGF gradient. Phosphoinositide 3-kinase 
signaling then stimulates the stretch of the endothelial cell, while attachment of the endothelial 
cell’s focal adhesion occurs. The focal adhesion’s attached stress fibers then contracts due to 
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stimulation of the Rho kinase pathway. Finally, integrin-focal adhesion kinase inside-out 
signaling occurs to release focal adhesions from the fibronectin extracellular matrix. This 
pathway is dynamic as the VEGFR2 interacts with α5β3 intergin receptor, another receptor that 
stimulates endothelial cell migration through regulating VEGFR2 signaling and stimulating 
assembly of focal adhesion by activating focal adhesion kinase.  
 Experiments carried out on Class 1 aaRSs, with a monomeric structure, such as YARS 
and tryptophanyl-tRNA synthetase have shown that these enzymes have angiogenic and 
angiostatic properties affecting VEGF migration pathway(K. Wakasugi, 2002). The phenomenon 
of regulation of angiogenesis in both enzymes was found to occur through proteolysis of YARS 
and WARS, which a portion of the enzyme acts as a signal molecule to activate/inhibit 
endothelial cell migration through inhibition of ERK (K. Wakasugi, 2002; Keisuke Wakasugi & 
Schimmel, 1999). These experiments opened the possibility that aaRs enzymes may have 
important roles in angiogenesis that are outside of their housekeeping function. This led to 
investigation on bacterial threonyl-tRNA synthetase (TARS) inhibitor, borrelidin (BN), as a 
potential antiangiogenic agent as it was discovered to suppress metastasis in mouse models 
(Funahashi et al., 1999).  
BN was isolated from Streptomyces species and was identified to bind to bacterial TARS 
in Escherichia coli (E. coli) cells (Olano et al., 2004; Paetz & Nass, 1973). Studies on BN 
resistant hamster ovary cells showed that BN also targeted eukaryotic cells, which suggest that 
angiogenesis occurs through TARS (Gerken & Arfin, 1984). However, BN is unable to examine 
physiological activity as its cytotoxic in normal epithelial cells. Variants of BN varying C17 side 
chain, such as BC194, were developed to reduce the cytotoxic effect (Wilkinson et al., 2006). 
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The Lounsbury/Francklyn lab became intrigued about the antiangiogenic effect of BN 
after recently observing secretion of TARS in endothelial through VEGF signaling in ovarian 
cancer (Tamara F. Williams, Adam C. Mirando, Barrie Wilkinson, Christopher S. Francklyn, & 
Karen M. Lounsbury, 2013). Recently, in vitro angiogenic assays studies showed that 
extracellular TARS increases the amount of blood vessel branching. This finding led to the 
theory that TARS acts as an extracellular signal to stimulate endothelial cell migration.  
Recent crystallization studies on TARS bound to BC194 and BN have shown to interact 
hydrophobic interaction in the catalytic site of TARS and inducing an open conformation (Adam 
C. Mirando et al., 2015). Theories from these studies suggest that the conformational change of 
TARS is the key to the inhibition of angiogenic activity.  However, it’s not fully understood 
whether inducing conformation of TARS or inhibiting the amino-transfer reaction is effective 
way to reduce angiogenesis. 
 Current studies turn towards generating BN resistant TARS mutants to compare level of 
angiogenic activity (Adam C. Mirando et al., 2015). Most mutant TARS that have the same 
open-lock conformation but still present catalytic activity can be formed by changing an amino 
acid within the binding pocket to a bulky amino acid, like tryptophan. Examining the clef 
structure of TARS showed that Q566 site is a potential area of inducing the open conformation 
without losing any function of the enzyme (Fang et al., 2015). 
At the same time, studies looked at generating BN resistant TARS that had loss of 
aminoacyl-transfer activity. Kinetic analysis had showed that H309 on bacteria TARS (H388 in 
human) had low level of aminoacyl transfer after converting site to alanine (Minajigi & 
Francklyn, 2008). This possible target as H388 is also an amino acid that is known to bind to 












In this study, mutants Q566W and H388A wild type human TARS were analyzed to see 
any changes in angiogenesis activity. These mutants were generated from E. coli to see whether 
inducing conformational change or inhibition of TARS catalytic activity reduces angiogenic 
activity respectively. To investigate whether the mutation site affected the angiogenic activity, 
tube assay formation was used (DeCicco-Skinner et al., 2014). The technique mimics the 
formation of blood vessels by utilizing human umbilical vascular endothelial cells (HUVECs). 
The cells grow under negative control media, positive control media, and low concentration of 
Figure 1. Crystal structure identified amino acids within 
TARS that bind to the angiogenic inhibitor BC194. Interaction 
shown by dotted lines. From Adam C. Mirando et al., 2015. 
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WT, Q566W, and H388A TARS enzymes, and measures the number of tubes formed by using 
the plugin Angiogenesis Analyzer on ImageJ. 
The mutants in this study were successfully purified and tested in the angiogenesis assay. 
Thus far, Q566W mutant didn’t change the level of tube production while H388A had high 
levels of activity. This shows support for the idea that neither changing conformation nor 
removing catalytic function reduces angiogenetic activity. However, the study found that TARS 
angiogenic activity is dose-dependent, as TARS had low level of activity at 200 nM than 100nM. 
This influences the comparison tube assay results to have no difference of activity. This is 
similar to studies on dose response angiogenic activity on integrin inhibitors.  Future studies on 
Q566W and H388A TARS mutants as well as integrin inhibitor dose response under 100nM 
TARS should be investigated using in vitro tube formation assay. 
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II. Materials and Methods   
Generating mutant forms of TARS: 
N-terminal His6-tagged human wildtype TARS sequence was purified using the 
QIAprep® spin miniprep kit (Qiagen). Plasmid DNA concentration was recorded at an 
absorbance at 260nm provided by UVM DNA Analysis facility’s Nanodrop. 
Purified TARS plasmid was mutated at the desired site using the QuikChange II 
Mutagenesis kit provided by Agilent Technologies. The mutant DNA plasmid was inserted into 
XL-10 competent blue cells (Agilent) and JM109 cells (Promega). These cells were selected in 
the prescence of Kamamycin and Chloramphenicol. Bacteria colonies were harvested for mutant 
DNA strains using QIAprep® spin miniprep kit (Qiagen). Purified mutant genes were verified 
using the University of Vermont’s (UVM) DNA sequencing facility. Validated mutated genes 
were inserted into E. coli. RosettaTM 2(DE3) pLac cells for expression and purification. Mutants 
Q566W and H388A were developed from this method. 
Purification of TARS: 
Purification of wild type and mutant versions of human TARS were performed by 
techniques described in Mirando et al. 2015.  Transformed E. coli cultures, containing TARS 
plasmids with recombinant His6-tag gene, were grown in LB containing 10 ug/ml Kanamycin 
and 10 ug/ml Chloramphenicol and were shaken at 37 oC until cell density reached 0.6 at 600nM. 
Expression of TARS was induced with 5mM isopropyl 1-thio-β-D-galactoside at 18 oC 
overnight. 
After bacterial expression, the E. coli. culture was subjected to centrifugation at 7000 rpm 
for 10 min at 4 oC. The E. coli. cell pellet was resuspended in sonication buffer (cold 20 mM 
KH2PO4, 100 mM KCl, 35 mM Imidazole, 5 mM β-mercaptoethanol (B-ME)) and lysed by 
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sonication. The sonicate was spun at 11,000 rpm for 30 minutes. The lysate was saturated to 
0.1% Protamine Sulfate to precipitate DNA plasmid, followed by centrifugation using the 
condition described above.  
TARS supernatant was loaded onto a 5 mL HisTrapTM FF column (GE Healthcare) 
equilibrated with the sonication buffer and run at a flow rate of 0.75 mL/min. HisTrap column 
was washed using the same sonication buffer and eluted by an imidazole gradient of 35-250 mM 
through 20 column volumes. Fractions yielding high peak absorbance at 280nm (A280) was run 
on an 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and stained 
with GelCodeTM Blue (Thermo Scientific) to detect presence of TARS. Pooled fractions 
containing TARS were dialyzed in buffer A (50 mM KH2PO4 pH: 6.8, 5% glycerol and 5 mM B-
ME).  
The dialyzed TARS was further purified in a 23 mL CHT-Tricorn Hydroxyapatite 
column using the buffer A as the equilibration and wash solution. Once washed, the 
hydroxyapatite column was eluted using pH gradient from buffer A to buffer B (500 mM 
KH2PO4 pH: 8, 5% glycerol and 5 mM B-ME). Fractions yielding high A280 detecting for TARS 
using SDS-PAGE. Purified TARS were dialyzed and stored in storage buffer C (20 mM HEPES 
pH:8, 100 mM KCl, 5 mM B-ME 40% glycerol). Concentration of TARS in storage solution was 
recorded at A280 provided by UVM DNA Analysis facility’s Nanodrop.  TARS samples were 
verified with Western blot stained in 1:500 TARS anti-mouse in 3% bovine serum albumin 
(BSA), 0.1% Azide, and Tris-buffered saline and Tween 20/Triton X-100 (TBST) (Abnova).  
 
Tube Assay Formation Technique: 
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 The Tube Assay was performed as described by Williams et al., 2015. Cultured 
HUVECs, between passages 3-7, were trypsinized and aliquoted onto a 48-well plate, coated 
with MatrigelTM (Basement Membrane Matrix Growth Factor Reduced; BD Biosciences) at a 5 x 
105 cells/ml concentration in Endothelial basal media (EBM media).  Cells were incubated in the 
following treatments: EBM media (negative control), EGM media with 10% fetal bovine serum 
(positive control), EBM media with 0.2 uM wild type TARS, 0.2 uM Q566W TARS, and 0.2 uM 
H388A TARS. Cells were incubated for 4-6 hours, washed twice with phosphate buffered saline 
(PBS) and fixed with 10% Formalin for 30 min. HUVECs were then washed again with PBS, 
followed by incubation in 1:150 Oregon green 488 Phallodin in 3% BSA/TBST (Molecular 
Probes), then washed again with PBS. These cells were imaged using an inverted fluorescence 
microscope (Olympus IX70) provided by UVM’s microscope imaging center. The number of 
Endothelial branches, pieces, and branching length were quantified using the Angiogenesis 
Analyzer plugin on Image J software.  For dose-response experiments, a similar Tube Formation 
Assay was done using TARS concentrations ranging from 10 nM to 500 nM to view effects of 
fibronectin binding to Matrigel.  
 
Statistical Analysis 
 All experimental values were presented as means ± SEM and analyzed by one-way 






Expression Mutant TARS Plasmids 
 Mutant TARS plasmids purified from the mutagenesis included Q566W and H388A.  For 
example, the H388A plasmid was inserted onto XL-10 gold compacted cells and JM109 cells for 
selection and was sequenced to verify the mutation site. The image of the H388A sequence can 













The bases highlighted represents the three-letter codon for amino acid 388. The wildtype amino 
acid encodes for histidine while the mutant plasmid encodes for alanine. The sequence data 
verifies correct base change and proper selection of E. coli cells based on the codon table. This 




Figure 2. Results of mutation site of H388A in JM109 Competent 
Cells sequenced using DNA Sequencher in DNA facility. Highlighted 




Purified TARS enzymes 
 Wild type TARS, Q566W, and H388A were purified from E. coli cells by saturating 
sample with protamine sulfate, followed by His6Tag and HA chromatography. SDS-PAGE 
results verified the presence of protein with a ~83kDa molecular weight, the molecular weight of 
TARS subunits (Figure 3).  Western blot of concentrated protein further verified the presence of 












Figure 3. An 8% SDS-PAGE Gel stained with GelCodeTM Blue (Thermo 
Scientific) presenting purified TARS wild type and mutants showing the correct 
molecular weight (~83kDa).  
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Both data verify the purification of TARS. However, the Western blot demonstrates that earlier 
purification of wild-type TARS contained contaminants that shared similar characteristic of 
TARS.  
Tube Assay Formation: 
 Previous data suggested that a point mutation at Q566W would result in decreased tube 
formation compared to wildtype TARS(Adam Christopher Mirando, 2015) . To confirm this, 
Q566W was tested against both positive, and negative controls, as well as wildtype TARS 




Figure 4. Expressed protein detected by TARS antibodies. Shown is a Western blot analysis of 8% SDS-
PAGE Gel presenting purified TARS wild type and mutants. Blot was stained in 1:500 TARS anti-
mouse in 3% BSA, 0.1% Azide, TBST (Abnova). Lane A: Q566W TARS (50ng), Lane B: WT TARS 



















Figure 5. Representative images of HUVECs grown on MatrigelTM and stained with 
1:150 Phalloidin Oregon green. Image A: Treated with EBM media (negative control), 
Image B: Treated with 2% EGM media (positive control), Image C: Treated with EBM 
media and 200nM TARS, Image D: Treated with EBM media and 200nM Q566W, and 








Although the tube assay results showed a visual trend, neither Q566W nor wildtype TARS had a 
significant quantitative difference in the number of tubes relative to the negative control (Figure 
6).  A possible explanation of this results comes from TARS having low angiogenic activity 
compared to earlier studies performing tube assays (Tamara F. Williams et al., 2013). In 
addition, the negative control groups had higher baseline tubes than in previous assays. More 
trials should be performed to reduce random error of low angiogenic activity in TARS. As 
discussed below, experiments that studied the dose-dependent effects of TARS also provide an 







The H388 site was also investigated, as this site is known to interact with Borrelidin and tRNAThr 
(Figure 1). It was found that the H388A mutation had the most number of tubes compared to the 
treatments, making it seem that removal of catalytic site of stimulates TARS induced 
angiogenesis (Figure 7). However, this stems from the wildtype TARS not show any tube 
Figure 6. (A,B,C) Quantification of HUVECs Tube Assay in response EBM Media, EGM media, 
wild type TARS, and Q566W TARS. Treatments were measured using Image JTM Angiogenesis 
Analyzer and statistics were recorded in Graphpad V7. (A) Comparing the sum number of tube pieces 
formed for each treatment. (B) Comparing the sum number of branches formed for each treatment. 
(C) Comparing the branch length of tubes for each treatment. 
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formation. It should be noted that only one trial was performed comparing the H388A mutants. 
More trials of H388A against wild type TARS should be done before a conclusion can be made. 
Like the results with the Q566W mutant, the dose-dependent effects of TARS need to be 





Figure 7. (A,B,C) Quantification of HUVECs Tube Assay in response EBM Media, EGM 
media, wild type TARS, Q566W, and H388A TARS. Treatments were measured using 
Image JTM Angiogenesis Analyzer and statistics were recorded in Graphpad V7. (A) 
Comparing the sum number of tube pieces formed for each treatment. (B) Comparing the 
sum number of branches formed for each treatment. (C) Comparing the branch length of 




Dose response of TARS in tube assay: 
  In the experiments described above, 200 nM wild-type TARS was used for stimulating 
tubes because that concentration proved to be effective for other investigators using previous 
TARS protein preparations. However, the current results showed variable or even inhibitory 
effects of TARS on tube formation of HUVECs using that dose. There was a concern that the 
different TARS preparations may exhibit different effects on the tube assay or that TARS at high 
concentrations may inhibit tube formation. To address this question, a dose response of TARS in 
the Tube Assay was performed at concentrations from 10 nM to 500 nM. The results revealed 
that TARS induced tube formation at concentrations up to 100 nM but higher concentrations led 
to a reduced effect, with loss of cell contact at 500 nM (Figure 8). As a result, tubes formed 
through the earlier experiments resulted in some tubes falling out of the Matrigel due to the 
inhibitory effect. This property of TARS led to a low amount of tubes forming in response to 





Figure 8 (a & b) HUVECs dose response bell curve data for wild type TARS. HUVECs were 
exposed to various concentration TARS ranging from 10nM to 500nM and were assayed using 
in vitro endothelial tube assay. HUVECs were fixed with 10% formalin and stained in 1:150 




Similar experiments were performed with mutants Q566W and H388A. A dose response 
with mutant Q566W revealed the lowest angiogenic activity occurred around 200 nM; while 
H388A inhibitory effects occurred around 50 nM (Figure 9). The results demonstrated that 
mutant Q566W was at peak concentration in earlier studies to perform inhibitory effects, 













Figure 9 (a,b,c,d) HUVEC Dose Response bell curve data for mutant TARS. HUVECs were exposed 
various concentration of mutant TARS ranging from 10nM to 500nM were assayed using in vitro 
endothelial tube assay. Graphs above represents mutants Q566W (a&b) and H388A (c&d) dose response 
curve respectively.  
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IV.  Discussion 
Investigation of Q566W site 
 Prior studies have proposed that Q566W mutant was shown to decrease angiogenic 
activity due to mimicking BC194 bound TARS open conformation disrupting protein-protein 
interaction (Adam Christopher Mirando, 2015). Based on ANOVA, the in vitro Tube Assay 
results oppose this idea because mutant Q566W does not show significant change of angiogenic 
activity compared to the wildtype TARS enzyme. However, only a few trials have been done 
comparing mutants to wild type TARS, and there are questions regarding the concentrations of 
TARS preparations, thus more tests are needed to confirm these results. 
Inhibition of TARS amino-transferring activity causes increase angiogenic activity 
 Purified H388A was generated to observe whether inhibition of TARS amino-transfer 
activity affects the level of angiogenic activity. This study has found that H388A has increased 
the angiogenic activity level of wildtype TARS and seemed to be more potent in the dose 
response assay.  It is clear from these studies that the TARS concentrations that elicit optimal 
activity need to be carefully titrated. Future investigation should perform dose response tube 
assays before comparing to wildtype TARS. 
Concentration of purified TARS affects HUVECs affinity to fibronectin  
 During the tube assay experiments, TARS also exhibited signs of excess migration with 
HUVECs that led to loss of cell contact. These trends are seen in both wild type and mutant 
derivatives of TARS indicating that there is a concentration threshold of TARS to use for 
HUVECs tube assay before tubes fall off. This may be a result of TARS having an effect of 
fibronectin formation as fibronectin is necessary to bind to Matrigel well. The removal of 
fibronectin would result in HUVECs being removed as well as the tubes formed. Based on the 
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curve, it seems that a concentration of around 100nM for wildtype TARS is the peak of 
observing tube formation. Studies on dose response curve on Matrigel binding to fibronectin 
reveal that most angiogenic activators, like VEGF, stimulates migration of HUVECs resulting in 
falling off the wells when washing. Investigation of the fibronectin binding with Matrigel is a 
potential gateway of understanding TARS migration phenomenon as fibronectin is found to bind 
to integrin receptors causing formation of actin filament stress fibers and attachment of focal 
adhesion to matrix (Danen, Sonneveld, Brakebusch, Fässler, & Sonnenberg, 2002). Future study 
using the fibronectin inhibitor (RGDS) in the tube assay is underway, as a comparison between 
wildtype dose response and RGDS could verify this idea (Reynolds et al., 2009). 
Troubleshooting in vitro endothelial tube assay technique 
Growth of Tubes Formation 
 A key issue in the tube assay experiments was timing. Although earlier studies mentioned 
HUVECs tube formation peak occurs around 6 hrs, the experiments performed had variations of 
peak formation between 4 hrs to 8 hrs (T. F. Williams, A. C. Mirando, B. Wilkinson, C. S. 
Francklyn, & K. M. Lounsbury, 2013).  In some cases, the tubes were under development in 
EGM media when being fixed. To prevent under developed tubes in future studies, monitoring 
both positive and negative control of HUVECs tube formation every 3 hrs is recommended. 
Verifying correct TARS concentration 
 Another issue in the tube assay experiments was the TARS concentration. Seen in the 
dose response, TARS concentration does play a role in angiogenic response. In earlier 
purifications, concentrations of purified wildtype TARS, Q566W, and H388A were recorded and 
diluted down to 20uM concentration to be used for tube assays. However, testing diluted version 
concentration using similar nanodrop technique revealed higher level of concentration than 
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expected. This was resolved prior to performing dose response experiments. Future experiments 
should nanodrop diluted TARS samples to ensure correct concentration as this could possibly 
influence the angiogenic response. 
Research significance in ovarian cancer treatment 
 The goal of the project was to investigate how TARS activity stimulates angiogenesis in 
ovarian cancer. As discussed earlier in the study, angiogenesis is necessary component to cancer 
cell environment as its used to create an “escape route” for tumor cells to travel to different 
tissues and provide nutrition for the cells to live. Research in oncology has come to understand 
this method and begin developing antiangiogenic therapies.  Developing known knockout 
enzyme, such as Q566W, could impact on anti-angiogenetic researcher as this would show 
mechanistically how TARS induces angiogenesis and how inhibitors such as BC194 and 
possibly RGDS inhibits activity. This would lead to development of better detection of severity 
of ovarian cancer compared to low detection molecules like Mucin-16 (Vaughan et al., 2011). 
Also, development of inhibitors such as BC194 and RGDS can make a major impact as a future 
targeted therapy against ovarian cancer cells (Vaughan et al., 2011).    
Conclusions 
 The angiogenic activity of TARS mutants Q566W and H388A has been successfully 
studied. Q566W does not show any difference in angiogenic activity with wild type TARS, while 
H388A shows an increase in activity. As mentioned, only a few trials were performed in this 
study, so further trials of in vitro tube assay should be done. Future studies should continue 
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